194 related articles for article (PubMed ID: 15739554)
21. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.
Lidar Z; Mardor Y; Jonas T; Pfeffer R; Faibel M; Nass D; Hadani M; Ram Z
J Neurosurg; 2004 Mar; 100(3):472-9. PubMed ID: 15035283
[TBL] [Abstract][Full Text] [Related]
22. Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin.
Murad GJ; Walbridge S; Morrison PF; Garmestani K; Degen JW; Brechbiel MW; Oldfield EH; Lonser RR
Clin Cancer Res; 2006 May; 12(10):3145-51. PubMed ID: 16707614
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
[TBL] [Abstract][Full Text] [Related]
24. Clinical studies with targeted toxins in malignant glioma.
Rainov NG; Söling A
Rev Recent Clin Trials; 2006 May; 1(2):119-31. PubMed ID: 18473963
[TBL] [Abstract][Full Text] [Related]
25. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
26. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
27. Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001).
Rainov NG; Heidecke V
J Neurooncol; 2004 Jan; 66(1-2):197-201. PubMed ID: 15015787
[TBL] [Abstract][Full Text] [Related]
28. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
Debinski W; Obiri NI; Powers SK; Pastan I; Puri RK
Clin Cancer Res; 1995 Nov; 1(11):1253-8. PubMed ID: 9815919
[TBL] [Abstract][Full Text] [Related]
29. hIL-13-PE38QQR. NeoPharm.
Barth S
Curr Opin Investig Drugs; 2001 Sep; 2(9):1309-13. PubMed ID: 11717820
[TBL] [Abstract][Full Text] [Related]
30. Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas.
Chittiboina P; Heiss JD; Warren KE; Lonser RR
J Neurosurg Pediatr; 2014 Mar; 13(3):276-82. PubMed ID: 24410126
[TBL] [Abstract][Full Text] [Related]
31. Convection-enhanced delivery in clinical trials.
Hall WA; Rustamzadeh E; Asher AL
Neurosurg Focus; 2003 Feb; 14(2):e2. PubMed ID: 15727423
[TBL] [Abstract][Full Text] [Related]
32. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
34. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Sampson JH; Akabani G; Archer GE; Berger MS; Coleman RE; Friedman AH; Friedman HS; Greer K; Herndon JE; Kunwar S; McLendon RE; Paolino A; Petry NA; Provenzale JM; Reardon DA; Wong TZ; Zalutsky MR; Pastan I; Bigner DD
Neuro Oncol; 2008 Jun; 10(3):320-9. PubMed ID: 18403491
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.
Puri RK
Methods Mol Biol; 2001; 166():155-76. PubMed ID: 11217365
[No Abstract] [Full Text] [Related]
36. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury.
Smith JS; Cha S; Mayo MC; McDermott MW; Parsa AT; Chang SM; Dillon WP; Berger MS
J Neurosurg; 2005 Sep; 103(3):428-38. PubMed ID: 16235673
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
[TBL] [Abstract][Full Text] [Related]
38. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
[TBL] [Abstract][Full Text] [Related]
39. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.
Debinski W; Obiri NI; Pastan I; Puri RK
J Biol Chem; 1995 Jul; 270(28):16775-80. PubMed ID: 7622490
[TBL] [Abstract][Full Text] [Related]
40. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.
Husain SR; Obiri NI; Gill P; Zheng T; Pastan I; Debinski W; Puri RK
Clin Cancer Res; 1997 Feb; 3(2):151-6. PubMed ID: 9815666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
